TLSIWNGM

TriSalus Life Sciences, Inc.

-31.2% · 90d

$0.86

+0.01 (+1.18%)

News

No News Yet

Press releases and SEC filings for TLSIW will appear here as they are published.

Check back later for updates

Key Data

Market Cap—

Open$1.11

Prev Close$0.85

Day Range$0.86 – $0.87

52W Range$0.80 – $5.00

Volume716

P/E (TTM)—

EPS—

Dividend Yield—

Beta0.54

Profit Margin-86.88%

Revenue Growth59.80%

About

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

102 employees

trisaluslifesci.com

Top Institutional Holders

As of 2025-12-31 · prior 2025-09-30

CAPTRUST FINANCIAL ADVISORS$152,401

21,834 sh+0.0%

JDM Financial Group LLC$3,699

530 sh0.0%

ROTHSCHILD INVESTMENT LLC$7

1 sh● NEW

See all holders →

Quarterly Financials

09/25

Revenue Net Income